Symbicort®: A better way to treat asthma?
Metadata[+] Show full item record
Current asthma guidelines suggest the preferred treatment for moderate-persistent and severe-persistent asthma include both an ICS and LABA. Recent evidence has shown that the addition of a LABA to an ICS is more beneficial for asthma control than an ICS alone. Until recently, Advair Diskus has been the only combination of LABA/ICS available for use in the United States. Symbicort, much like Advair, is intended only for patients who are not adequately controlled on other asthma controller medications, generally low- to mediumdose ICS.
Evidence Based Practice 11(1): 11+.